164 related articles for article (PubMed ID: 37597079)
1. Timing is Everything: Neoadjuvant Versus Adjuvant Immunotherapy in Patients with Resectable Metastatic Melanoma.
Holder AM; Wargo JA; Ross MI
Ann Surg Oncol; 2023 Nov; 30(12):6953-6957. PubMed ID: 37597079
[No Abstract] [Full Text] [Related]
2. Correction: Timing is Everything: Neoadjuvant Versus Adjuvant Immunotherapy in Patients with Resectable Metastatic Melanoma.
Holder AM; Wargo JA; Ross MI
Ann Surg Oncol; 2023 Nov; 30(12):7688. PubMed ID: 37661225
[No Abstract] [Full Text] [Related]
3. Neoadjuvant immunotherapy for melanoma.
Lee AY; Brady MS
J Surg Oncol; 2021 Mar; 123(3):782-788. PubMed ID: 33002195
[TBL] [Abstract][Full Text] [Related]
4. Neoadjuvant Checkpoint Immunotherapy and Melanoma: The Time Is Now.
Long GV; Menzies AM; Scolyer RA
J Clin Oncol; 2023 Jun; 41(17):3236-3248. PubMed ID: 37104746
[TBL] [Abstract][Full Text] [Related]
5. The Current State of Neoadjuvant Therapy in Resectable Advanced Stage Melanoma.
Bushara O; Tidwell J; Wester JR; Miura J
Cancers (Basel); 2023 Jun; 15(13):. PubMed ID: 37444454
[TBL] [Abstract][Full Text] [Related]
6. Neoadjuvant treatments in patients with high-risk resectable stage III/IV melanoma.
Spagnolo F; Croce E; Boutros A; Tanda E; Cecchi F; Mascherini M; Solari N; Cafiero F; Queirolo P
Expert Rev Anticancer Ther; 2020 May; 20(5):403-413. PubMed ID: 32326767
[No Abstract] [Full Text] [Related]
7. Multidisciplinary treatment strategies in high-risk resectable melanoma: Role of adjuvant and neoadjuvant therapy.
McKean MA; Amaria RN
Cancer Treat Rev; 2018 Nov; 70():144-153. PubMed ID: 30195813
[TBL] [Abstract][Full Text] [Related]
8. Neoadjuvant Immunotherapy in Melanoma: The Paradigm Shift.
Hieken TJ; Kreidieh F; Aedo-Lopez V; Block MS; McArthur GA; Amaria RN
Am Soc Clin Oncol Educ Book; 2023 Jan; 43():e390614. PubMed ID: 37116111
[TBL] [Abstract][Full Text] [Related]
9. Neoadjuvant plus adjuvant dabrafenib and trametinib versus standard of care in patients with high-risk, surgically resectable melanoma: a single-centre, open-label, randomised, phase 2 trial.
Amaria RN; Prieto PA; Tetzlaff MT; Reuben A; Andrews MC; Ross MI; Glitza IC; Cormier J; Hwu WJ; Tawbi HA; Patel SP; Lee JE; Gershenwald JE; Spencer CN; Gopalakrishnan V; Bassett R; Simpson L; Mouton R; Hudgens CW; Zhao L; Zhu H; Cooper ZA; Wani K; Lazar A; Hwu P; Diab A; Wong MK; McQuade JL; Royal R; Lucci A; Burton EM; Reddy S; Sharma P; Allison J; Futreal PA; Woodman SE; Davies MA; Wargo JA
Lancet Oncol; 2018 Feb; 19(2):181-193. PubMed ID: 29361468
[TBL] [Abstract][Full Text] [Related]
10. Neoadjuvant checkpoint inhibitor immunotherapy for resectable mucosal melanoma.
Ho J; Mattei J; Tetzlaff M; Williams MD; Davies MA; Diab A; Oliva ICG; McQuade J; Patel SP; Tawbi H; Wong MK; Fisher SB; Hanna E; Keung EZ; Ross M; Weiser R; Su SY; Frumovitz M; Meyer LA; Jazaeri A; Pettaway CA; Guadagnolo BA; Bishop AJ; Mitra D; Farooqi A; Bassett R; Faria S; Nagarajan P; Amaria RN
Front Oncol; 2022; 12():1001150. PubMed ID: 36324592
[TBL] [Abstract][Full Text] [Related]
11. Neoadjuvant plus adjuvant combined or sequenced vemurafenib, cobimetinib and atezolizumab in patients with high-risk, resectable BRAF-mutated and wild-type melanoma: NEO-TIM, a phase II randomized non-comparative study.
Ascierto PA; Cioli E; Chiarion-Sileni V; Quaglino P; Spagnolo F; Guidoboni M; Del Vecchio M; Peris K; Queirolo P; Fioretto L; Caracò C; Paone M; Sorrentino A; Capone M; Giannarelli D; Ferrara G; Massi D; Trojaniello C
Front Oncol; 2023; 13():1107307. PubMed ID: 36845751
[TBL] [Abstract][Full Text] [Related]
12. Treatment Approaches for Melanomas That Relapse After Adjuvant or Neoadjuvant Therapy.
Ng G; Xu W; Atkinson V
Curr Oncol Rep; 2022 Oct; 24(10):1273-1280. PubMed ID: 35639333
[TBL] [Abstract][Full Text] [Related]
13. Neoadjuvant immune checkpoint inhibitors in high-risk stage III melanoma.
Ferraresi V; Vari S
Hum Vaccin Immunother; 2022 May; 18(3):1971015. PubMed ID: 34882516
[TBL] [Abstract][Full Text] [Related]
14. Neoadjuvant Immunotherapy for NSCLC: Current Concepts and Future Approaches.
Uprety D; Mandrekar SJ; Wigle D; Roden AC; Adjei AA
J Thorac Oncol; 2020 Aug; 15(8):1281-1297. PubMed ID: 32522713
[TBL] [Abstract][Full Text] [Related]
15. Adjuvant and neoadjuvant therapies in resectable pancreatic cancer: a systematic review of randomized controlled trials.
D'Angelo FA; Antolino L; La Rocca M; Petrucciani N; Magistri P; Aurello P; Ramacciato G
Med Oncol; 2016 Mar; 33(3):28. PubMed ID: 26883935
[TBL] [Abstract][Full Text] [Related]
16. Educational Review: Neoadjuvant Approaches to Melanoma.
Sharon CE; Karakousis GC
Ann Surg Oncol; 2022 Dec; 29(13):8492-8500. PubMed ID: 35849287
[TBL] [Abstract][Full Text] [Related]
17. Neoadjuvant Immunotherapy for High-Risk, Resectable Malignancies: Scientific Rationale and Clinical Challenges.
Krishnamoorthy M; Lenehan JG; Maleki Vareki S
J Natl Cancer Inst; 2021 Jul; 113(7):823-832. PubMed ID: 33432320
[TBL] [Abstract][Full Text] [Related]
18. Neoadjuvant Treatments for Advanced Resectable Melanoma.
Liu JY; Lowe M
J Surg Oncol; 2019 Jan; 119(2):216-221. PubMed ID: 30589079
[TBL] [Abstract][Full Text] [Related]
19. Neoadjuvant Therapy for Melanoma.
Lowe MC; Kudchadkar RR
Surg Oncol Clin N Am; 2020 Jul; 29(3):445-453. PubMed ID: 32482319
[TBL] [Abstract][Full Text] [Related]
20. Neoadjuvant immunotherapy of locoregionally advanced solid tumors.
Tarhini AA; Eads JR; Moore KN; Tatard-Leitman V; Wright J; Forde PM; Ferris RL
J Immunother Cancer; 2022 Aug; 10(8):. PubMed ID: 35973745
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
